A cutting-edge diagnostic test is helping some doctors find diagnoses for medical mysteries by analyzing DNA and RNA to ...
Concurrent DNA and RNA sequencing revealed 15.3% more patients with actionable variants than DNA sequencing alone.
Tejas Savant’s rating is based on Illumina’s position as a leading player in the next-generation sequencing market, supported by its innovative platform that offers high throughput sequencing at lower ...
We recently published a list of UBS’ Top Quant Stocks In AI, IT, Healthcare & Other Sectors: Top 33 Stocks In All Sectors. In ...